13F filer · CIK 2052213
Elmind Capital, LP
NEW YORK, NY · filing since Q4 2025 · last filing Aug 14, 2026
Reported value
$398.0M
+$45.8M vs prior
Positions
35
New / sold out
6 / 5
Added / reduced
9 / 6
Turnover
19.5%
buys $86.1M · sells $73.1M
Top-10 weight
66.6%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Added | RELAY THERAPEUTICS INC | +928,333 | +172.9% | +$17.4M |
| New | LEGEND BIOTECH CORP | +570,569 | – | +$16.5M |
| Added | VIRIDIAN THERAPEUTICS INC | +450,000 | +84.1% | +$8.3M |
| Added | VAXCYTE INC | +135,840 | +42.9% | +$7.9M |
| New | SUMMIT THERAPEUTICS INC | +493,820 | – | +$7.2M |
| New | INSMED INC | +65,000 | – | +$6.9M |
| Added | TRAVERE THERAPEUTICS INC | +115,000 | +64.8% | +$6.5M |
| Added | CELLDEX THERAPEUTICS INC NEW | +125,000 | +14.5% | +$4.7M |
| Added | CULLINAN THERAPEUTICS INC | +160,000 | +30.2% | +$2.9M |
| Added | SUPERNUS PHARMACEUTICALS | +50,000 | +250.0% | +$2.3M |
5 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | KALVISTA PHARMACEUTICALS INC | -1,021,300 | -100.0% | $-20.6M |
| Sold out | CG ONCOLOGY INC | -291,800 | -100.0% | $-19.7M |
| Reduced | TYRA BIOSCIENCES INC | -330,000 | -94.3% | $-10.5M |
| Reduced | MBX BIOSCIENCES INC | -120,000 | -56.9% | $-6.6M |
| Reduced | BIOCRYST PHARMACEUTICALS INC | -480,000 | -48.0% | $-4.8M |
| Reduced | UROGEN PHARMA LTD | -100,000 | -45.5% | $-3.7M |
| Sold out | APELLIS PHARMACEUTICALS INC | -50,000 | -100.0% | $-2.0M |
| Reduced | VERA THERAPEUTICS INC | -45,982 | -9.5% | $-2.0M |
| Reduced | DESIGN THERAPEUTICS INC | -100,000 | -48.1% | $-1.4M |
| Sold out | ENGENE HOLDINGS INC | -210,000 | -100.0% | $-1.4M |
1 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | COGENT BIOSCIENCES INCCOM | 1,170,740 | $45.3M | 11.38% |
| 2 | SYNDAX PHARMACEUTICALS INCCOM | 1,855,000 | $40.6M | 10.19% |
| 3 | CELLDEX THERAPEUTICS INC NEWCOM NEW | 990,000 | $36.8M | 9.25% |
| 4 | RELAY THERAPEUTICS INCCOM | 1,465,279 | $27.4M | 6.89% |
| 5 | VAXCYTE INCCOM | 452,340 | $26.3M | 6.61% |
| 6 | VERA THERAPEUTICS INCCL A | 436,518 | $18.7M | 4.71% |
| 7 | PHARVARIS N VCOM | 525,750 | $18.2M | 4.57% |
| 8 | VIRIDIAN THERAPEUTICS INCCOM | 984,931 | $18.1M | 4.55% |
| 9 | CYTOMX THERAPEUTICS INC.COM | 4,550,000 | $17.1M | 4.29% |
| 10 | TRAVERE THERAPEUTICS INCCOM | 292,600 | $16.6M | 4.18% |
25 more rows. Subscribe for $29/month to see every row, download the data and use the API.